Skip to main content

Obese

5
Pipeline Programs
11
Companies
9
Clinical Trials
0
Approved Products

Pipeline by Development Stage

Preclinical
Phase 1
Phase 1/2
Phase 2
Phase 2/3
Phase 3
On Market
0
2
0
3
0
0
0
Early DiscoveryClinical DevelopmentMarket

Competitive Landscape

10 companies ranked by most advanced pipeline stage

Structure Therapeutics
Structure TherapeuticsSOUTH SAN FRANCISCO, CA
1 program
1
AleniglipronPhase 2
Biocorp
BiocorpFrance - Issoire
1 program
1
AleniglipronPhase 21 trial
Active Trials
NCT07400588Active Not Recruiting58Est. Sep 2026
Hanmi Pharmaceutical
1 program
1
HM15275Phase 21 trial
Active Trials
NCT07205900Active Not Recruiting267Est. Jan 2027
NGM Biopharmaceuticals
1 program
1
NGM313Phase 11 trial
Active Trials
NCT03298464Completed25Est. Jul 2018
Innovation Pharmaceuticals
1 program
1
ProbioticPhase 11 trial
Active Trials
NCT05878444Unknown15Est. Jan 2024
Human BioSciences
Human BioSciencesWV - Martinsburg
1 program
CPAPN/A1 trial
Active Trials
NCT02086448Completed242Est. Feb 2022
Angeles Therapeutics
Angeles TherapeuticsCA - Los Angeles
1 program
Goal-Directed Financial IncentivesN/A1 trial
Active Trials
NCT03157713Completed668Est. Mar 2021
Pfizer
PfizerNEW YORK, NY
1 program
Growth hormone treatmentN/A1 trial
Active Trials
NCT01421589Completed15Est. Mar 2013
Purdue Pharma
Purdue PharmaCT - Stamford
1 program
Learned: Non-nutritive beverage to Non-nutritive beverageN/A1 trial
Active Trials
NCT01550133Completed60Est. Dec 2016
Rivus Pharmaceuticals
Rivus PharmaceuticalsVA - Charlottesville
1 program
HU6 TabletPHASE_11 trial
Active Trials
NCT05433506Completed30Est. Mar 2023

Trial Timeline

Clinical trial activity over time

2021
2022
2023
2024
2025
2026
2027
Hanmi PharmaceuticalHM15275
BiocorpAleniglipron
Innovation PharmaceuticalsProbiotic
Rivus PharmaceuticalsHU6 Tablet
NGM BiopharmaceuticalsNGM313
Angeles TherapeuticsGoal-Directed Financial Incentives
Human BioSciencesCPAP
Purdue PharmaLearned: Non-nutritive beverage to Non-nutritive beverage
PfizerGrowth hormone treatment

Clinical Trials (9)

Total enrollment: 1,380 patients across 9 trials

NCT07205900Hanmi PharmaceuticalHM15275

Study to Evaluate HM15275 in Obese or Overweight Subjects Without Diabetes Mellitus

Start: Dec 2025Est. completion: Jan 2027267 patients
Phase 2Active Not Recruiting
NCT07400588BiocorpAleniglipron

Aleniglipron Phase 2 in Type 2 Diabetes Mellitus

Start: Dec 2025Est. completion: Sep 202658 patients
Phase 2Active Not Recruiting
NCT05878444Innovation PharmaceuticalsProbiotic

Evaluation of the Colonization Capacity of a Probiotic Bacterium.

Start: Jun 2023Est. completion: Jan 202415 patients
Phase 1Unknown
NCT05433506Rivus PharmaceuticalsHU6 Tablet

Safety and Pharmacokinetics of HU6

Start: Sep 2022Est. completion: Mar 202330 patients
Phase 1Completed
NCT03298464NGM BiopharmaceuticalsNGM313

Study of NGM313 in Obese Participants

Start: Sep 2017Est. completion: Jul 201825 patients
Phase 1Completed
NCT03157713Angeles TherapeuticsGoal-Directed Financial Incentives

Financial Incentives for Weight Reduction Study

Start: Oct 2017Est. completion: Mar 2021668 patients
N/ACompleted
NCT02086448Human BioSciencesCPAP

Sleep Disordered Breathing, Obesity and Pregnancy Study (SOAP)

Start: Sep 2014Est. completion: Feb 2022242 patients
N/ACompleted
NCT01550133Purdue PharmaLearned: Non-nutritive beverage to Non-nutritive beverage

Effects of Food Form on Cephalic Phase Responses

Start: Sep 2012Est. completion: Dec 201660 patients
N/ACompleted
NCT01421589PfizerGrowth hormone treatment

Growth Hormone Treatment on Phosphocreatine Recovery in Obesity

Start: Sep 2011Est. completion: Mar 201315 patients
N/ACompleted

Phase Legend

Preclinical— Lab & animal studies
Phase 1— Safety & dosing
Phase 2— Efficacy testing
Phase 3— Large-scale trials
On Market— Approved & available

Key Insights

11 companies competing in this space

The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.